Detalhe da pesquisa
1.
Oral Iptacopan Monotherapy in Paroxysmal Nocturnal Hemoglobinuria.
N Engl J Med
; 390(11): 994-1008, 2024 Mar 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-38477987
2.
Treatment outcomes of complement protein C5 inhibition in 509 UK patients with paroxysmal nocturnal hemoglobinuria.
Blood
; 143(12): 1157-1166, 2024 Mar 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-38142401
3.
Alternative donor transplantation for severe aplastic anemia: a comparative study of the SAAWP EBMT.
Blood
; 2024 Apr 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-38643511
4.
Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromes.
Blood
; 141(17): 2047-2061, 2023 04 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-36724453
5.
Germ line DDX41 mutations define a unique subtype of myeloid neoplasms.
Blood
; 141(5): 534-549, 2023 02 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36322930
6.
Current use of androgens in bone marrow failure disorders: a report from the Severe Aplastic Anemia Working Party of the European Society for Blood and Marrow Transplantation.
Haematologica
; 109(3): 765-776, 2024 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37199126
7.
Real-world experience of pegcetacoplan in paroxysmal nocturnal hemoglobinuria.
Am J Hematol
; 99(5): 816-823, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38348608
8.
Phase 2 study of danicopan in patients with paroxysmal nocturnal hemoglobinuria with an inadequate response to eculizumab.
Blood
; 138(20): 1928-1938, 2021 11 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-34314483
9.
Paroxysmal nocturnal hemoglobinuria: Where are we going.
Am J Hematol
; 98 Suppl 4: S33-S43, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36794458
10.
VEXAS syndrome (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) for the dermatologist.
J Am Acad Dermatol
; 89(6): 1209-1214, 2023 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-35121074
11.
Concomitant Immunosuppressive Therapy and Eculizumab Use in Patients with Paroxysmal Nocturnal Hemoglobinuria: An International PNH Registry Analysis.
Acta Haematol
; 146(1): 1-13, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-36108594
12.
The Effect of Respiratory Viral Infections on Breakthrough Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria.
Int J Mol Sci
; 24(11)2023 May 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-37298309
13.
Long-term safety and efficacy of ravulizumab in patients with paroxysmal nocturnal hemoglobinuria: 2-year results from two pivotal phase 3 studies.
Eur J Haematol
; 109(3): 205-214, 2022 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-35502600
14.
Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study.
Blood
; 133(6): 540-549, 2019 02 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-30510079
15.
Danicopan: an oral complement factor D inhibitor for paroxysmal nocturnal hemoglobinuria
Haematologica
; 106(12): 3188-3197, 2021 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33121236
16.
Characterization of breakthrough hemolysis events observed in the phase 3 randomized studies of ravulizumab versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria.
Haematologica
; 106(1): 230-237, 2021 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31949012
17.
Association between red blood cell transfusion dependence and burden in patients with myelodysplastic syndromes: A systematic literature review and meta-analysis.
Eur J Haematol
; 107(1): 3-23, 2021 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-33715214
18.
One-year outcomes from a phase 3 randomized trial of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria who received prior eculizumab.
Eur J Haematol
; 106(3): 389-397, 2021 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-33301613
19.
Pharmacokinetic and pharmacodynamic effects of ravulizumab and eculizumab on complement component 5 in adults with paroxysmal nocturnal haemoglobinuria: results of two phase 3 randomised, multicentre studies.
Br J Haematol
; 191(3): 476-485, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32449174
20.
AI for AA: machine learning makes an entry.
Blood
; 141(17): 2040-2042, 2023 04 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-37103950